indemakitug (EI-001) / Elixiron Immunotherap - LARVOL DELTA

A Randomized, Double-blind, Placebo-controlled Proof-of-concept Study of EI-001 in Non-segmental Vitiligo Patients (clinicaltrials.gov) - P2 | N=45 | Not yet recruiting | Sponsor: Elixiron Immunotherapeutics (Hong Kong) Ltd.

New P2 trial • Dermatology • Immunology • Vitiligo

First in Human Study of EI-001 Monoclonal Antibody in Healthy Volunteers (clinicaltrials.gov) - P1 | N=35 | Completed | Sponsor: Elixiron Immunotherapeutics Limited | Recruiting ➔ Completed

Trial completion

First in Human Study of EI-001 Monoclonal Antibody in Healthy Volunteers (clinicaltrials.gov) - P1 | N=36 | Recruiting | Sponsor: Elixiron Immunotherapeutics Limited | Trial completion date: Dec 2022 ➔ Apr 2025 | Trial primary completion date: Dec 2022 ➔ Feb 2025

Trial completion date • Trial primary completion date

Targeting the Elevated IFN-γ in Vitiligo Patients by Human Anti- IFN-γ Monoclonal Antibody Hampers Direct Cytototoxicity in Melanocyte (WCD 2023) - "The strong positive correlation between the level of IFN-γ in the lesion skin and the level of IFN-γ, CXCL9, and CXCL10 in plasma indicating that plasma level of IFN-γ, CXCL9 and CXCl10 could be used as predictors for lesional IFN-γ. In vitro studies using an IFN-γ neutralizing antibody, EI-001, further elucidate the impacts of IFN-γ in vitiligo pathogenesis and support the use of IFN-γ inhibitor for treating vitiligo"

Clinical • Dermatology • Immunology • Vitiligo • CD4 • CD8 • CXCL10 • CXCL9 • CXCR3 • GZMB • IFNG • MITF

First in Human Study of EI-001 Monoclonal Antibody in Healthy Volunteers (clinicaltrials.gov) - P1 | N=36 | Recruiting | Sponsor: Elixiron Immunotherapeutics Inc. | Not yet recruiting ➔ Recruiting | Trial completion date: Jun 2022 ➔ Dec 2022 | Trial primary completion date: Jun 2022 ➔ Dec 2022

Enrollment open • Trial completion date • Trial primary completion date

First in Human Study of EI-001 Monoclonal Antibody in Healthy Volunteers (clinicaltrials.gov) - P1; N=36; Not yet recruiting; Sponsor: Elixiron Immunotherapeutics Inc.

New P1 trial